By: Caitlin A. Koppenhaver

Florida’s effort to create a new licensure framework for medical spas has come to an end for the 2026 legislative session. HB 1429, which would have established a new Board of Pharmacy-driven oversight structure for certain medical spa operations, last saw action on March 13, 2026, when it died in the House Health Professions & Programs Subcommittee.

That is a welcome result, and not because the medical spa and wellness space should exist without oversight.

Our earlier article explained that HB 1429 would have created the Medical Spa Prescription Drug Oversight Act, placing a broad range of medspa activities into a new Board of Pharmacy-centered licensing structure. As written, the bill was not limited to one narrow practice model or one isolated concern. It was expansive enough to touch businesses involved in weight-loss services, hormone therapy, longevity care, botulinum toxin treatments, IV therapies, and other wellness services involving prescription products.

The concern was never whether Florida should promote patient safety and accountability in this area. Those goals are important, and they are shared across the healthcare industry. Medical spas, pharmacies, and other healthcare participants operate in a setting that involves prescribing, supervision, drug handling, advertising, documentation, and professional responsibility. Meaningful regulation has an important role in supporting those objectives.

The more difficult question was whether this particular bill was the right fit for the industry as it exists today.

Florida already has an established regulatory framework in this space. Physicians, physician assistants, nurse practitioners, pharmacists, pharmacies, and other licensed professionals are already governed by licensure laws, scope-of-practice rules, prescribing requirements, delegation standards, and disciplinary oversight. Consumer protection laws also remain in play. In addition to those standards, HB 1429 would have added another layer, this time at the facility level, under a pharmacy-oriented model that may have been appropriate for some circumstances, but not necessarily for the full range of businesses that could have been swept in.

That is why the bill’s failure should not be read as opposition to regulation. It is better understood as recognition that regulation is most effective when it is closely tailored to the specific concerns it is intended to address.

If there are particular concerns about unsafe prescribing, insufficient supervision, improper storage or handling of drugs, misleading marketing, or poor documentation, those issues can and should be addressed directly. But a bill that casts a very wide net across an already regulated and highly varied industry can create burden without enough precision. When that happens, the law can begin to function less like a targeted public-safety measure and more like a broad structural framework.

That concern was especially pronounced here because Florida already has tools to investigate and respond to misconduct. Businesses that cut corners, misstate services, prescribe inappropriately, or otherwise fall short of legal requirements are not operating in a vacuum. Existing law already gives regulators multiple avenues to review and discipline that conduct.

It is important to keep in mind that none of this means the industry gets a pass. Medspas and wellness businesses in Florida still need to pay close attention to how they are structured, how services are provided, who is prescribing, who is administering, how products are sourced and handled, what their marketing says, and how records are maintained. Those obligations did not disappear because HB 1429 died.

Still, the bill’s failure leaves Florida in a better position than a hurried or overinclusive licensing scheme would have. It preserves room for a more thoughtful legislative approach in the future, one that is narrower, more deliberate, and better matched to the specific risks lawmakers may want to address.

That is why this outcome should be viewed positively. Not because oversight is unnecessary, but because broad new regulation is not always the best form of regulation, particularly where a substantial body of existing law is already in place.